Additionally, the current study identified four SNP associated with objective responses to erlotinib: rs1042640 in UGT1A10, rs1060463, and rs1064796 in CYP4F11 and rs2074900 in CYP4F2. Previous studies have shown that CYP450 family members function in cancer drug metabolism, including in NSCLC. This evidence concerns the gene UGT1A10 and non-small cell lung carcinoma.